Incidencia y factores de riesgo en la ototoxicidad por cisplatino

  1. Benito Orejas, José Ignacio 1
  2. Sánchez-Martínez, Ana 2
  3. Tavárez-Rodríguez, Juan José 3
  4. Morais-Pérez, Darío 1
  5. Soto De Prado-Otero, Diego 1
  6. Muñoz-Moreno, María Fe 1
  1. 1 SACYL, Hospital Clínico Universitario de Valladolid, España
  2. 2 Red del Servicio Madrileño de Salud. Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, España.
  3. 3 SACYL, Hospital General Río Carrión de Palencia, España.
Zugehörigkeit anzeigen +
Zeitschrift:
Revista ORL

ISSN: 2444-7986,  2444-7986

Datum der Publikation: 2021

Ausgabe: 12

Ausgabe: 3

Seiten: 217-230

Art: Artikel

DOI: 10.14201/ORL.24411 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Andere Publikationen in: Revista ORL

Zusammenfassung

Introduction and objectives: Cisplatin is one of the drugs with greater ototoxicity within clinical use. Hearing loss detection and therapeutic measures can be done in early stages by controlling the auditory thresholds of patients on treatment. With this paper we intend to assess the incidence and severity of hearing loss by cisplatin in our environment, identifying major risk factors. Methods: The case study was conducted on a third level hospital by monitoring and recording the hearing loss by cisplatin among the first 100 patients who accepted the audiologic monitoring. Those patients were sent by the oncology department. Then a high frequency audiometry and the otoacoustic emissions was carried out on the patients to evaluate them. Results: Essentially, we refer to a group which us made up of adults with an average age of 59 years old. Out of the 70 patients treated only with cisplatin, 27% experienced hearing loss. Among the remaining 30 patients who received radiotherapy in addition to cisplatin, hearing impairment at 53% was detected. Cisplatin ototoxic effects are dose-dependent and more intense with normal hearing. In our results, gender, age or the presence of previous hearing loss, were not statistically significant factors in vulnerability. Conclusions: the susceptibility variable to ototoxic damage on patients, the clinically insidious onset of hearing loss and its irreversibility, justify the need to monitor the cisplatin ototoxicity. Clinical data allow us to calculate the risk of an average population, although it does not help to predict what will happen to each patient.

Bibliographische Referenzen

  • American Academy of Audiology. American Academy of Audiology Position Statement and guidelines: Ototoxicity monitoring.https://audio¬logyweb.s3.amazonaws.com/migrated/OtoMon- Guidelines.pdf_539974c40999c1.58842217.pdf. (2009). Accessed 6 Agosto 2018.
  • American Speech-Language-Hearing Associa¬tion. Audiologic management of patients recei¬ving cochleotoxic drug therapy [guidelines]. https://www.asha.org/policy/GL1994-00003.htm. (1994). Accessed 6 Agosto 2018.
  • Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O. Platinum Compound-Related Ototoxicity in Children: Long-Term Follow-Up Reveals Continuous Worsening of Hearing Loss. J Pediatr Hematol Oncol. 2004 Oct;26(10):649-655.
  • Biro K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, et al. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology. 2006;70(3):177- 84.
  • Bokemeyer C, Berger CC, Hartmann JT, Koll¬mannsberger C, Schmoll HJ, Kuczyk MA, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998 Apr;77(8):1355-62.
  • Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19(4):295-300.
  • Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pedia¬tric Oncology Boston ototoxicity scale. J Clin Oncol. 2012 Jul 1;30(19):2408-17. doi: 10.1200/ JCO.2011.39.1110.
  • Brooks B, Knight K. Ototoxicity monitoring in children treated with platinum chemothe¬rapy. Int J Audiol. 2017 Jul 24:1-7. doi: 10.1080/14992027.2017.1355570.
  • Caballero M, Mackers P, Reig O, Buxo E, Nava¬rrete P, Blanch JL, et al. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer. Oncology. 2017;93(2):75- 82. doi: 10.1159/000468522.
  • Campbell KCM, Le Prell CG. Drug-Induced Ototoxicity: Diagnosis and Monitoring. Drug Saf. 2018 May;41(5):451-464. doi: 10.1007/s40264- 017-0629-8.
  • Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol. 2010 Apr 1;28(10):1788- 95. doi: 10.1200/JCO.2009.24.4228.
  • Cheraghi S, Nikoofar P, Fadavi P, Bakhshandeh M, Khoie S, Gharehbagh EJ, et al. Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy. Med Oncol. 2015 Jul;32(7):200. doi: 10.1007/s12032-015-0646-3.
  • Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff- Dinnesen A, Tissing WJ, Loonen JJ, et al.; DCOG-LATER, The Netherlands. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. Eur J Cancer. 2016 Dec;69:77-85. doi: 10.1016/j.ejca.2016.09.023.
  • Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007 Jun;29(6):355-60.
  • Crundwell G, Gomersall P, Baguley DM. Ototoxicity (cochleotoxicity) classifications: A review. Int J Audiol. 2016;55(2):65-74. doi: 10.3109/14992027.2015.1094188.
  • DeBacker JR, Harrison RT, Bielefeld EC. Long- Term Synergistic Interaction of Cisplatin- and Noise-Induced Hearing Losses. Ear Hear. 2017 May/Jun;38(3):282-291. doi: 10.1097/ AUD.0000000000000391.
  • Einarsson EJ, Petersen H, Wiebe T, Fransson PA, Grenner J, Magnusson M, et al. Long term hearing degeneration after platinum-based chemotherapy in childhood. Int J Audiol. 2010 Oct;49(10):765- 71. doi: 10.3109/14992027.2010.485595.
  • Fausti SA, Wilmington DJ, Helt PV, Helt WJ, Konrad-Martin D. Hearing health and care: the need for improved hearing loss prevention and hearing conservation practices. J Rehabil Res Dev. 2005 Jul-Aug;42(4 Suppl 2):45-62.
  • García-Berrocal JR, Nevado J, González-García JA, Sánchez-Rodríguez C, Sanz R, Trinidad A, et al. Heat shock protein 70 and cellular distur¬bances in cochlear cisplatin ototoxicity model. J Laryngol Otol. 2010 Jun;124(6):599-609. doi: 10.1017/S0022215110000496.
  • Garinis AC, Cornell A, Allada G, Fennelly KP, Maggiore RJ, Konrad-Martin D. Ototoxicity monitoring through the eyes of the treating physician: Perspectives from pulmonology and medical oncology. Int J Audiol. 2017 Oct 5:1-6. doi: 10.1080/14992027.2017.1381769.
  • Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics. 2010 Apr;125(4):e938-50. doi: 10.1542/peds.2009-1597.
  • Helson L, Okonkwo E, Anton L, Cvitko¬vic E. cis-Platinum ototoxicity. Clin Toxicol. 1978;13(4):469-78.
  • Helt-Cameron J, Allen PJ. Cisplatin ototoxicity in children: implications for primary care providers. Pediatr Nurs. 2009 Mar-Apr;35(2):121-7.
  • Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social develop¬ment. J Clin Oncol. 2005 Dec 1;23(34):8588-96.
  • Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007 Apr 1;25(10):1190-5.
  • Konrad-Martin D, James KE, Gordon JS, Reavis KM, Phillips DS, Bratt GW, et al. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring. J Am Acad Audiol. 2010 May;21(5):301-14; quiz 357. doi: 10.3766/ jaaa.21.5.3.
  • Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):81-100. doi: 10.1682/JRRD.2013.04.0092.
  • Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013 Aug;34(8):458-69. doi: 10.1016/j.tips.2013.05.006.
  • Li Y, Womer RB, Silber JH. Predicting cispla¬tin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004 Nov;40(16):2445-51.
  • Lonsbury-Martin BL, Martin GK. Evoked otoacoustic emissions as objective screeners for ototoxicity. Semin Hearing. 2001;22(4):377-91.
  • Marco-Algarra J, Basterra J, Marco J. Cis-diami¬nedichloro platinum ototoxicity. An experimental study. Acta Otolaryngol. 1985 Mar-Apr;99(3- 4):343-7.
  • Maru D, Malky GA. Current practice of ototoxi¬city management across the United Kingdom (UK). Int J Audiol. 2018 Apr 20:1-13. doi: 10.1080/14992027.2018.1460495.
  • Olgun Y, Aktaş S, Altun Z, Kırkım G, Kızmazoğlu DÇ, Erçetin AP, et al. Analysis of genetic and non genetic risk factors for cisplatin ototoxi¬city in pediatric patients. Int J Pediatr Otorhi¬nolaryngol. 2016 Nov;90:64-69. doi: 10.1016/j. ijporl.2016.09.001.
  • Sakamoto M, Kaga K, Kamio T. Extended high-frequency ototoxicity induced by the first admi¬nistration of cisplatin. Otolaryngol Head Neck Surg. 2000 Jun;122(6):828-33.
  • Sánchez-Martínez A, Benito-Orejas J, Tavárez- Rodríguez J, Hernández-Santos M, Morais-Pérez D, Soto-Prado D. Monitorización de la ototoxici¬dad por cisplatino. Revista ORL [Internet]. 1 Mar 2018 [citado 9 Ago 2018]; 9(1): 25-33. Disponible en: http://revistas.usal.es/index.php/2444-7986/ article/view/16774.
  • Schmidt CM, Knief A, Lagosch AK, Deuster D, am Zehnhoff-Dinnesen A. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected. Ear Hear. 2008 Dec;29(6):830-7. doi: 10.1097/AUD.0b013e31818005a4.
  • Stavroulaki P, Apostolopoulos N, Segas J, Tsaka¬nikos M, Adamopoulos G. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol. 2001 May 31;59(1):47-57.
  • Theunissen EA, Bosma SC, Zuur CL, Spijker R, van der Baan S, Dreschler WA, et al. Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature. Head Neck. 2015 Feb;37(2):281-92. doi: 10.1002/hed.23551.
  • Theunissen EA, Zuur CL, Józwiak K, Lopez- Yurda M, Hauptmann M, Rasch CR, et al. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy. JAMA Otolaryngol Head Neck Surg. 2015 Sep;141(9):810-5. doi: 10.1001/ jamaoto.2015.1515.
  • Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cispla¬tin-associated ototoxicity in pediatric onco¬logy patients. Pediatr Blood Cancer. 2012 Jul 15;59(1):144-8. doi: 10.1002/pbc.24138.
  • Yu KK, Choi CH, An YH, Kwak MY, Gong SJ, Yoon SW, Shim HJ. Comparison of the effecti¬veness of monitoring Cisplatin-induced ototoxi¬city with extended high-frequency pure-tone audiometry or distortion-product otoacoustic emission. Korean J Audiol. 2014 Sep;18(2):58-68. doi: 10.7874/kja.2014.18.2.58.
Fuente de los datos: Dialnet